Opioid Induced Constipation Therapeutics
1. Amitiza patent expiration
Treatment: Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable exci...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US8071613 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8114890 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US5284858 | SUCAMPO PHARMA LLC | Prostaglandins E and anti ulcers containing same |
Jul, 2014
(11 years ago) | |
| US8088934 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
May, 2021
(4 years ago) | |
| US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(3 years ago) | |
| US6583174 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6414016 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US7417067 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US8097649 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(3 years ago) | |
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 3 months ago) | |
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(4 months ago) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(1 year, 14 days from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(1 year, 9 months from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Dosage: CAPSULE
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
2. Movantik patent expiration
Treatment: Treatment of opioid-induced constipation
MOVANTIK's oppositions filed in EPO
MOVANTIK IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662365 | AVERITAS | Polymer conjugates of opioid antagonists |
Oct, 2022
(3 years ago) | |
| US7786133 | AVERITAS | Chemically modified small molecules |
Sep, 2028
(2 years from now) | |
| US9012469 | AVERITAS | Crystalline naloxol-peg conjugate |
Apr, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617530 | AVERITAS | Polymer conjugates of opioid antagonists |
Oct, 2022
(3 years ago) | |
| US8067431 | AVERITAS | Chemically modified small molecules |
Dec, 2024
(1 year, 23 days ago) | |
| US7056500 | AVERITAS | Polymer conjugates of opioid antagonists |
Jun, 2024
(1 year, 6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Dosage: TABLET
How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage
MOVANTIK family patents
3. Relistor patent
expiration
Treatment: Treatment of opioid-induced constipation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6559158 | SALIX | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(8 years ago) | |
| US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(5 years from now) | |
| US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Dosage: TABLET
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
4. Relistor patent expiration
Treatment: Treatment of opioid-induced constipation; Treatment of opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its tre...
RELISTOR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US6559158 | SALIX PHARMS | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(8 years ago) | |
| US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 9 months ago) | |
| US12303592 | SALIX PHARMS | Formulations for parenteral delivery of compounds and uses thereof |
Aug, 2027
(1 year, 6 months from now) | |
| US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(4 years from now) | |
| US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(1 year, 9 months ago) | |
| US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 9 months ago) | |
| US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Dosage: SOLUTION
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
5. Symproic patent expiration
Treatment: Treatment of opioid-induced constipation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536192 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(8 months from now) | |
| US8084460 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(2 years from now) | |
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(8 months from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Feb, 2031
(5 years from now) | |
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(5 years from now) | |
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350377 | BDSI | NA |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents